In This Issue
The Study of Diabetic Nephropathy With Atrasentan (SONAR) and Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) trials showed kidney-protective effects of an endothelin A receptor antagonist (ERA) and a sodium glucose co-transporter 2 (SGLT2) inhibitor in patients with type-2 diabetes and chronic kidney disease, respectively. A lim iting effect of ERA is fluid retention, and diuresis is a consequence of SGLT2 inhibition.
Source: Kidney International - Category: Urology & Nephrology Tags: In This Issue Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Invokana | SGLT2 Inhibitors | Sodium | Study | Urology & Nephrology